Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENERA: Aflibercept in Neovascular Glaucoma
NCT03639675Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2018
- Primary completion
- Feb 2019
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aflibercept in neovascular glaucoma (NVG), sponsored by Bayer. Primary endpoint: Change in Intraocular Pressure From Baseline to Week 1. Started Oct 2018; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on NCT03639675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639675.